Is Bliss GVS Pharma overvalued or undervalued?

As of 19 November 2025, Bliss GVS Pharma's valuation grade has moved from fair to attractive, indicating a more favorable assessment of its market position. The company is currently considered undervalued, with a PE ratio of 15.51, an EV to EBITDA of 12.52, and a PEG ratio of 0.88, all of which suggest that it is trading at a discount compared to its peers.
In comparison to its industry peers, Bliss GVS Pharma's valuation metrics stand out positively. For instance, Sun Pharma has a significantly higher PE ratio of 37.07, while Divi's Lab is even more expensive at 68.85. Additionally, Cipla and Dr. Reddy's Labs, both classified as attractive, have PE ratios of 22.64 and 18.06, respectively. Despite a recent underperformance relative to the Sensex on a year-to-date basis, Bliss GVS Pharma has shown strong returns over the past year, outperforming the index with a return of 33.10% compared to 9.81% for the Sensex.